Ftse Mib
33.859,52
0,36%
DAX
17.962,83
0,32%
S&P 500
5.064,20
0,91%
NASDAQ
15.840,96
1,51%
Bitcoin
59.266,77
0,25%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Five Prime Therapeutics Inc (FPRX) Five Prime Therapeutics Inc (FPRX) Notizie

FPRX

Five Prime Therapeutics (FPRX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:FPRX
DataOraFonteTitoloSimboloCompagnia
15/02/202212:39Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:FPRXFive Prime Therapeutics Inc
22/04/202112:04Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:FPRXFive Prime Therapeutics Inc
20/04/202117:28TipRanksAmgen Completes The Acquisition Of Five Prime TherapeuticsNASDAQ:FPRXFive Prime Therapeutics Inc
20/04/202101:54Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:FPRXFive Prime Therapeutics Inc
16/04/202122:16Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:FPRXFive Prime Therapeutics Inc
16/04/202122:02Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:FPRXFive Prime Therapeutics Inc
16/04/202114:48Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or ...NASDAQ:FPRXFive Prime Therapeutics Inc
16/04/202114:43Edgar (US Regulatory)Amended Statement of Ownership: Solicitation (sc 14d9/a)NASDAQ:FPRXFive Prime Therapeutics Inc
16/04/202114:39Edgar (US Regulatory)Amended Tender Offer Statement by Third Party (sc To-t/a)NASDAQ:FPRXFive Prime Therapeutics Inc
16/04/202114:38Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:FPRXFive Prime Therapeutics Inc
16/04/202114:25PR Newswire (US)Amgen Successfully Completes Acquisition Of Five Prime TherapeuticsNASDAQ:FPRXFive Prime Therapeutics Inc
18/03/202113:02Edgar (US Regulatory)Tender Offer Statement by Third Party (sc To-t)NASDAQ:FPRXFive Prime Therapeutics Inc
09/03/202123:00Business WireFive Prime Cancels Fourth Quarter and Full-Year 2020 Financial Results Conference CallNASDAQ:FPRXFive Prime Therapeutics Inc
08/03/202123:02Edgar (US Regulatory)Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c)NASDAQ:FPRXFive Prime Therapeutics Inc
05/03/202122:20Edgar (US Regulatory)Written Communication Relating to an Issuer or Third Party (sc To-c)NASDAQ:FPRXFive Prime Therapeutics Inc
05/03/202109:57TipRanksAmgen Inks $1.9B Deal To Buy Five Prime Therapeutics; Shares Pop 79%NASDAQ:FPRXFive Prime Therapeutics Inc
04/03/202121:34Dow Jones NewsFive Prime Therapeutics Shares Gain After Amgen DealNASDAQ:FPRXFive Prime Therapeutics Inc
04/03/202115:20Dow Jones NewsAmgen to Acquire Five Prime Therapeutics for $1.9 Billion in CashNASDAQ:FPRXFive Prime Therapeutics Inc
04/03/202114:30PR Newswire (US)Amgen To Acquire Five Prime Therapeutics For $1.9 Billion in CashNASDAQ:FPRXFive Prime Therapeutics Inc
02/03/202122:05Business WireFive Prime Therapeutics Announces Timing of Its Fourth Quarter 2020 and Full Year Results Conference CallNASDAQ:FPRXFive Prime Therapeutics Inc
26/02/202123:00Business WireFive Prime Therapeutics to Participate in the Cowen 41st Annual Health Care ConferenceNASDAQ:FPRXFive Prime Therapeutics Inc
23/02/202100:00Business WireFive Prime Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare ConferenceNASDAQ:FPRXFive Prime Therapeutics Inc
16/02/202122:47Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:FPRXFive Prime Therapeutics Inc
05/02/202115:25Business WireFive Prime Therapeutics to Participate in Guggenheim Healthcare Talks 2021: Oncology DayNASDAQ:FPRXFive Prime Therapeutics Inc
15/01/202112:55Business WirePhase 2 FIGHT Trial Results Presented at ASCO GI Validate Importance of FGFR2b Overexpression & Reinforce Potential of Bemari...NASDAQ:FPRXFive Prime Therapeutics Inc
09/12/202023:00Business WireFive Prime to Present Phase 2 FIGHT Trial Results of Bemarituzumab at American Society of Clinical Oncology (ASCO) Gastrointe...NASDAQ:FPRXFive Prime Therapeutics Inc
17/11/202023:00Business WireFive Prime Announces Closing of Upsized Public Offering of Common StockNASDAQ:FPRXFive Prime Therapeutics Inc
13/11/202023:28Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:FPRXFive Prime Therapeutics Inc
13/11/202004:00Business WireFive Prime Announces Pricing of Upsized Public Offering of Common StockNASDAQ:FPRXFive Prime Therapeutics Inc
12/11/202012:11Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:FPRXFive Prime Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:FPRX

La tua Cronologia

BIT
ISP
Intesa Sanpaolo
BIT
STLAM
Stellantis NV
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
UCG
Unicredit
BIT
TIT
Telecom Italia
BIT
STMMI
ST Microelectronics
BIT
BPE
Bper Banca
BIT
ENI
Eni
BIT
ENEL
Enel
BIT
RACE
Ferrari NV
BIT
IVG
Iveco Group NV
BIT
BAMI
Banco BPM
BIT
TRN
Terna Trasmissione Elett...
BIT
SPM
Saipem
BIT
TEN
Tenaris
BIT
SRG
Snam
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network